A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...
NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...
TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market for Heart Defect Closure Devices - 2016 (Forecasted to 2022) - MedCore" report to their offering. As of ...
An innovative trans-catheter device closure of a secundum Atrial Septal Defect (ASD) or a hole in the centre of the wall between the two upper chambers of the heart in a 16-month-old baby girl Ovi has ...
Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation. Patients who are older and have ...
Expert Rev Cardiovasc Ther. 2007;5(6):1135-1146. Diagnosing a secundum ASD is more often than not incidental because the defect normally causes symptoms late in adult life. Echocardiography and MRI ...
Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback